Oklahoma scientists find interferon-beta may help MS patients on B cell therapy fight infections like flu and Covid-19, new ...

Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplan ...

Updated clinical data in heavily pre-treated, CAR-T naïve patients with B-NHL shows prolonged duration of response, with ...

Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million ...

BRIUMVI U.S. net revenue of $119.7 million. Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net ...

Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses. BRIUMVI is indicated in the U.S. for the treatment of adults with RMS ...

One of the best ways to maximize absorption is through proper gut health. Before trying vitamin supplements, it's important ...

AbolerIS Pharma has dosed the Phase I study’s first cohort subjects with its humanised anti-CD45 receptor-like protein C ...

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic ...

The potentially first-in-class drug, which targets CD20, is able to achieve "deep B-cell depletion" by stimulating cells of the immune system to engulf and destroy B-cells in the presence of a ...